With FDA nod, Regeneron brings an RNAi drug to autoimmune disease
BioPharma DiveBen FidlerNovember 19, 2026
The product of a collaboration with Alnylam, Livsayis is now Regeneron s first marketed RNAi drug and will compete against established medicines from AstraZeneca and Argenx.